Back to top
more

Denali Therapeutics (DNLI)

(Delayed Data from NSDQ)

$18.56 USD

18.56
1,762,397

+0.10 (0.54%)

Updated May 31, 2024 04:00 PM ET

After-Market: $18.59 +0.03 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DNLI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Denali Therapeutics Inc. [DNLI]

Reports for Purchase

Showing records 161 - 180 ( 184 total )

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

06/10/2020

Daily Note

Pages: 5

Let ''Er Rip! RIPK1 Candidate DNL788 Called Up As DNL747 Paused

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

06/10/2020

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

06/01/2020

Daily Note

Pages: 4

Preclinical TV Platform Proof of Concept Paves Way for DNL310 Readout Late 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

05/11/2020

Company Report

Pages: 7

Platform Validation Soon; Reit Buy and $28 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

05/08/2020

Daily Note

Pages: 19

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

04/03/2020

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

04/02/2020

Daily Note

Pages: 4

YACD (Yet Another COVID-19 Delay) - DNLI Well-Positioned To Maneuver

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

03/02/2020

Company Report

Pages: 7

Continue to Believe DNL310 May Provide Platform Validation; Reit Buy and $28 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

02/28/2020

Company Report

Pages: 10

Upgrade to Outperform; We''re Not Throwing Away Our Shot

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

02/28/2020

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

01/29/2020

Company Report

Pages: 7

With All Efforts On Track, DNLI Prices Offering

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

01/24/2020

Daily Note

Pages: 4

Awaiting Platform Thesis to Unfold in the Near-Term

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

01/10/2020

Daily Note

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

01/03/2020

Industry Report

Pages: 11

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

12/20/2019

Industry Report

Pages: 11

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

12/20/2019

Company Report

Pages: 6

Looking Ahead to 2020, Encouraged by Pipeline Development Across Lysosomal and Glial Programs; Reit Buy and $28 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

11/07/2019

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

11/07/2019

Company Report

Pages: 10

Uneventful 3Q19 Report, But Data LRRK''ing Around The Corner

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Denali Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

09/26/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party